30 Oct 2023 07:00
REDX PHARMA PLC
("Redx" or the "Company")
Redx to Present Preclinical Data on RXC009, a selective Discoidin Domain Receptor 1 inhibitor
RXC009, recently nominated as Redx's latest development candidate, is a potential first-in-class treatment for chronic kidney disease and associated fibrosis
Alderley Park, UK, 30 October 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer announces that it will present preclinical data from its recently-nominated development candidate, RXC009 at the American Society of Nephrology (ASN) Annual Meeting (2-5 November 2023, Philadelphia, PA).
Redx nominated RXC009 as a development candidate in October 2023. RXC009 is a small molecule, orally available, highly potent and selective DDR1 inhibitor and a potential first-in-class treatment for chronic kidney disease (CKD).
CKD affects 8% to 16% of the population worldwide and is most commonly attributed to diabetes and hypertension. Renal fibrosis, characterized by tubulointerstitial fibrosis and glomerulosclerosis, is one of the final manifestations of CKD as it progresses and is associated with high morbidity[1].
DDRs have recently gained traction as druggable targets with the potential to treat multiple fibrotic conditions, including kidney fibrosis associated with CKD such as in Alport Syndrome, but to date, no selective inhibitors of DDR1 have entered the clinic.
Dr Nicolas Guisot, Vice President, Drug Discovery at Redx, will make an oral presentation discussing preclinical data from studies of RXC009 in a validated animal model of CKD.
Details of the presentation are as follows:
Title: Development of Novel Selective DDR1 Inhibitors with the Potential to Treat CKD
| |
Day/Date: November 4, 2023
| |
Time: 4:48 - 4:57 pm
Location: Room 103, Pennsylvania Convention Center |
For further information, please contact: |
| ||||||
| |||||||
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications ir@redxpharma.com
Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 | ||||||
US Office Peter Collum, Chief Financial Officer | |||||||
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 | ||||||
Matt Davis/ Adam Dawes | |||||||
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 | ||||||
Claes Spång/ Satheesh Nadarajah/ David Wilson | |||||||
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 | ||||||
Rupert Dearden/ Freddy Crossley/ Emma Earl | |||||||
FTI Consulting | T: +44 (0)203 727 1000 | ||||||
Simon Conway/ Ciara Martin | |||||||
| |||||||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application during the fourth quarter of 2023. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development. In October 2023, Redx nominated its next development candidate, RXC009 a highly potent and selective DDR1 inhibitor for the treatment of chronic kidney disease and associated fibrosis.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
[1] Taken in part from Chen TK et al; JAMA. 2019 Oct 1; 322(13): 1294Ð1304.